|Table of Contents|

The research progress about the effect of chemotherapy and cytoreductive surgery on immune function in ovarian cancer patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 02
Page:
377-381
Research Field:
Publishing date:

Info

Title:
The research progress about the effect of chemotherapy and cytoreductive surgery on immune function in ovarian cancer patients
Author(s):
TIAN Lewei; WANG Hui
Department of Obstetrics and Gynecology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China.
Keywords:
ovarian cancer; immune system; chemotherapy; cytoreductive surgery
PACS:
R737.31
DOI:
10.3969/j.issn.1672-4992.2023.02.036
Abstract:
Since ovarian cancer is immune related,the special immunosuppressive microenvironment is created by tumor for the development of ovarian cancer.With the development of research,we can find that platinum-based chemotherapy have been confirmed to have the abilities to induce lymphocyte infiltration and activation especially CD8+T cells,and decrease the infiltration of regulatory T cell in tumor cells,improve the function of antigen presenting cells to promote antitumor immunity,up-regulate the expression of immune checkpoint suppressive molecules,improve the formation of immunosuppression,regulate the cytokine network and destroy the inflammatory environment that leads to tumor growth,improve the antitumor activities of peripheral lymphocytes,and so on.The surgery can also regulate the immune system by directly reducing the tumor load and increasing the infiltration of lymphocytes in tumor microenvironment.Hence the positive effects of first-line therapies on antitumor immune system,reinforcing the detection of changes in the immune function of patients having ovarian cancer during treatment may be helpful for the patients in the formulation of their treatment plans.

References:

［1］ZHANG Lin,CONEJO-GARCIA JR,KATSAROS D,et al.Intratumoral T cells,recurrence,and survival in epithelial ovarian cancer［J］.N Engl J Med，2003,348（3）:203-213.
［2］KATY MILNE，JOHN R WEBB，WINNIE SUN,et al.Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes［J］.J Transl Med，2012,（10）:33-45.
［3］MAGDALENA MARIA DUTSCH-WICHEREK,SEBASTIAN SZUBERT,KONRAD DZIOBEK,et al.Analysis of the treg cell population in the peripheral blood of ovarian cancer patients in relation to the long-term outcomes［J］.Ginekol Pol，2019,90(4):79-184.
［4］刘仕锦，林宇健，何嘉帅等.组织驻留CD8+T细胞在肿瘤中的研究进展［J］.中国肿瘤临床 2022，49（12）：622-626. LIU SHIJIN,LIN YUJIAN,HE JIASHUAI,et al.Research progress on tissue-resident CD8+T cells in tumors［J］.Chin J Clin Oncol,2022,49(12):622-626.
［5］CHIARA NAPOLETANO,FILIPPO BELLATI,RACHELE LANDI,et al.Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression［J］.J Cell Mol Med，2010，14(12):2748-2759.
［6］TL WHITESIDE.The tumor microenvironment and its role in promoting tumor growth［J］.Oncogene，2008，27(45),5904-5912.
［7］JIABO DI,TJITSKE DUIVEMAN-DE BOER,CARL G FIGDOR,et al.Aiming to immune elimination of ovarian cancer stem cells［J］.World J Stem Cells，2013，5(4):149-162.
［8］HWANG WEITING,SARAH F.ADAMS,EMIN TAHIROVIC,et al.Prognostic significance of tumor-infiltrating T cells in ovarian cancer:A meta-analysis［J］.Gynecol Oncol，2012，124(2):192-198.
［9］NICLAS C BLESSIN,WENCHAO LI,TIM MANDELKOW,et al.Prognostic role of proliferating CD8+cytotoxic Tcells in human cancers［J］.Cell Oncol(Dordr),2021,44(4):793-803.
［10］CARMEN M ANADON,XIAOQING YU,KAY HANGGI,et al.Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells［J］.Cancer Cell.2022,40(5):545-557.e13.
［11］WILLIAM H.HUDSON,JULIA GENSHEIMER,MASAO HASHIMOTO,et al.Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1 Stem-like CD8 T cells during chronic infection［J］.Immunity,2019,51(6),1043-1058.e4.
［12］LI CHUNXIAO,JIANG PING,WEI SHUHUA,et al.Regulatory T cells in tumor microenvironment:new mechanisms,potential therapeutic strategies and future prospects［J］.Mol Cancer，2020，19(1):116-139.
［13］YUTING JIANG,CHENGDI WANG,SHENGTAO ZHOU.Targeting tumor microenvironment in ovarian cancer:Premise and promise［J］.Biochim Biophys Acta Rev Cancer，2020,1873(2):188361-188371.
［14］MARION CURTIS,ABIR MUKHERJEE,ERNST LENGYEL.The tumor microenvironment takes center stage in ovarian cancer metastasis［J］.Trends Cancer，2018，4(8):517-551.
［15］DAIKO WAKITA,TOSHIKI IWAI,SUGURU HARADA,et al.Cisplatin augments antitumor T-Cell responses leading to a potent therapeutic effect in combination with PD-L1 blockade［J］.Anticancer Res，2019，39(4):1749-1760.
［16］SHANNON GRABOSCH,MIRNA BULATOVIC,FEITIANZHI ZENG,et al.Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles［J］.Oncogene，2019,38(13):2380-2393.
［17］IZABELA WINKLER,MAREK GOGACZ,ANETA ADAMIAK,et al.Regulatory T lymphocytes and transforming growth factor beta in epithelial ovarian tumors-prognostic significance［J］.J Ovarian Res，2015，8(1):39-49.
［18］STEFFEN BOHM,ANNE MONTFORT,OLIVER MT PEARCE,et al.Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma［J］.Clin Cancer Res，2016，22(12):3025-3036.
［19］CARLOS W WANDERLEY,DAVID F COLON,JOAO PAULO M.LUIZ,et al.Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an m1 profile in a TLR4-dependent manner［J］.Cancer Res，2018，78(20):5891-5900.
［20］DAPENG HAO,JIE LIU,MENG CHEN,et al.Immunogenomic analyses of advanced serous ovarian cancer reveal immune score is a strong prognostic factor and an indicator of chemosensitivity［J］.Clin Cancer Res，2018，24(15),3560-3571.
［21］JIN PENG,JUNZO HAMANISHI,NORIOMI MATSUMURA,et al.Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer［J］.Cancer Res，2015，75(23):5034-5045.
［22］SILVIA DARB-ESFAHANI,CATARINA ALISA KUNZE,HAGEN KULBE,et al.Prognostic impact of programmed cell death-1(PD-1)and PD-ligand 1(PD-L1)expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma［J］.Oncotarget，2016，7(2):1486-1499.
［23］STEPHANIE LHEUREUX,CHARLIE GOURLEY,IGNACE VERGOTE,et al.Epithelial ovarian cancer［J］.Lancet，2019，393(10177):1240-1253.
［24］ELODIE LAURET MARIE JOSEPH,AMOS KIRILOVSKY,BENOIT LECOESTER,et al.Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy［J］.J Immunother Cancer,2021,9(7):e002256.
［25］R LEIBOWITZ AMIT,Z SYMON,A ISRAEL,et al.Association between the absolute baseline lymphocyte count and response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer［J］.Clin Oncol(R Coll Radiol)，2016，28(12):790-796.
［26］HUANG JJ,JIANG WQ,LIN TY,et al.Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma,nasal type［J］.Ann Oncol，2011，22(1):149-155.
［27］ZHU Jiyu,LIU Chengcheng,WANG Liang,et al.Peripheral blood lymphocyte-to-monocyte ratio as a prognostic factor in advanced epithelial ovarian cancer:a multicenter retrospective study［J］.J Cancer，2017，8(5):737-743.
［28］GABRIELLA FERRANDINA,LUCA PIERELLI,ALESSANDRO PERILLO,et al.Lymphocyte recovery in advanced ovarian cancer patients after high-dose chemotherapy and peripheral blood stem cell plus growth factor support［J］.Clin Cancer Res，2003，9(1):195-200.
［29］冯勤梅，吴霞，狄文.卵巢癌患者化疗前后免疫细胞格局变化［J］.现代免疫学，2010,30（4）:337-341. FENG Qinmei,WU Xia,DI Wen.Changes of immune pattern in ovarian cancer patients before and after chemotherapy［J］.Current Immunology，2010,30(4):337-341.
［30］MARCO GREPPI,GIOVANNA TABELLINI,ORNELLA PATRIZI,et al.Strengthening the anti tumor NK cell function for the treatment of ovarian cancer［J］.Int J Mol Sci，2019,20(4):890-903.
［31］MAURICIO P PINTO,CARLOS BALMACEDA,MARIA L BRAVO,et al.Patient inflammatory status and CD4+/CD8+intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer［J］.Gynecol Oncol，2018，51(1):10-17.
［32］DONASTAS SAKELLARIOU-THOMPSON,MARIE-ANDREE FORGET,EMILY HINCHCLIF,et al.Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy［J］.Cancer Immunol Immunother，2019，68(11):1747-1757.
［33］M FELICES,S CHU,B KODAL,et al.IL-15 super-agonist(ALT-803)enhances natural killer(NK)cell function against ovarian cancer［J］.Gynecol Oncol，2017,145(3):453-461.
［34］LOCKE D UPPENDAHL,MARTIN FELICE,LAURA BENDZICK,et al.Cytokine-induced memory-like natural killer cells have enhanced function,proliferation,and in vivo expansion against ovarian cancer cells［J］.Gynecol Oncol，2019，153(1):149-157.
［35］ARISTOTELIS BAMIAS,VASILIKI KOUTSOUKOU,EVANGELOS TERPOS,et al.Correlation of NK T-like CD3+CD56+Cells and CD4+CD25+(hi)regulatory T cells with vegf and tnfalpha in ascites from advanced ovarian cancer:association with platinum resistance and prognosis in patients receiving first-line,platinum-based chemotherapy［J］.Gynecol Oncol，2008，108(2):421-427.
［36］SHUANG YE,WEI CHEN,YUWEI ZHENG,et al.Peripheral lymphocyte populations in ovarian cancer patients and correlations with clinicopathological features［J］.J Ovarian Res,2022，15(1):43.
［37］ANNE CRAVEIRO BROCHNER,SOREN MIKKELSEN,IORN HEGELUND,et al.The immune response is affected for at least three weeks after extensive surgery for ovarian cancer［J］.Dan Med J，2016,63(6):A5243.
［38］CHEN Wei,YE Shuang,WU Yutuan,et al.Changes in peripheral lymphocyte populations in patients with advanced/recurrent ovarian cancer undergoing splenectomy during cytoreductive surgery［J］.J Ovarian Res,2021,14(1):113.
［39］ELISENA FRANZESE,SARA CENTONZE,ANNA DIANA,et al.PARP inhibitors in ovarian cancer［J］.Cancer Treat Rev，2019,（73）:1-9.

Memo

Memo:
-
Last Update: 1900-01-01